JovenJMartin-ParederoVCampsJ. Treat-to-target low-density lipoprotein cholesterol: time to debate a too simple and dogmatic paradigm. Angiology. 2013.
2.
WhayneTFJr. Assessment of low-density lipoprotein targets. Angiology. 2013;64(6):411–416.
3.
The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251(3):351–364.
4.
The lipid research clinics coronary primary prevention trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251(3):365–374.
5.
BlankenhornDHJohnsonRLNessimSAAzenSPSanmarcoMESelzerRH. The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results. Control Clin Trials. 1987;8(4):356–387.
6.
BlankenhornDHNessimSAJohnsonRLSanmarcoMEAzenSPCashin-HemphillL. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257(23):3233–3240.
7.
BlankenhornDHSelzerRHMackWJ. Evaluation of colestipol/niacin therapy with computer-derived coronary end point measures. A comparison of different measures of treatment effect. Circulation. 1992;86(6):1701–1709.
8.
BuchwaldHStollerDKCamposCTMattsJPVarcoRL. Partial ileal bypass for hypercholesterolemia. 20- to 26-year follow-up of the first 57 consecutive cases. Ann Surg. 1990;212(3):318–329; discussion 329-331.
9.
BuchwaldHVarcoRLBoenJR. Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year posttrial follow-up report from the POSCH. Program on the Surgical Control of the Hyperlipidemias. Arch Intern Med. 1998;158(11):1253–1261.
10.
KroonAAAengevaerenWRvan der WerfT. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation. 1996;93(10):1826–1835.
11.
SchonfeldG. The hypobetalipoproteinemias. Annu Rev Nutr. 1995;15:23–34.
12.
WiviottSDCannonCPMorrowDARayKKPfefferMABraunwaldE. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol. 2005;46(8):1411–1416.
13.
AthyrosVGPapageorgiouAAMercourisBR. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin. 2002;18(4):220–228.
14.
HsiaJMacFadyenJGMonyakJRidkerPM. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin The JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J Am Coll Cardiol. 2011;57(16):1666–1675.
15.
VogelRA. PCSK9 inhibition: the next statin?J Am Coll Cardiol. 2012;59(25):2354–2355.
16.
WilhelmsenLPyoralaKWedelHCookTPedersenTKjekshusJ.Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment. Eur Heart J. 2001;22(13):1119–1127.
17.
MikhailidisDPElisafMRizzoM. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol. 2011;9(5):533–571.
Otocka-KmiecikAMikhailidisDPNichollsSJDavidsonMRyszJBanachM. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?Prog Lipid Res. 2012;51(4):314–324.
20.
WierzbickiASClarkeREViljoenAMikhailidisDP. Triglycerides: a case for treatment?Curr Opin Cardiol. 2012;27(4):398–404.
21.
RidkerPMBuringJERifaiNCookNR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297(6):611–619.
22.
GrundySM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol. 2006;47(6):1093–1100.
